Sasha Bernatsky
Overview
Explore the profile of Sasha Bernatsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
352
Citations
6767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan J, Bernatsky S, Lee J, Fortin P, Dayam R, Gingras A, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006651
: The Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases (SUCCEED) study was created to better understand COVID-19 vaccination in immune-mediated inflammatory disease (IMID). Knowing the frequency...
2.
Krustev E, Fritzler M, Bernatsky S, St Pierre Y, Sciore P, Vinet E, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39948002
No abstract available.
3.
Stanciu M, Lee J, McDonald E, Clark G, Pineau C, Kalache F, et al.
Lupus Sci Med
. 2025 Jan;
12(1).
PMID: 39884714
Objectives: Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised medication-related hospitalisations and their preventability. Methods: We identified consecutive admissions to our tertiary hospitals...
4.
Birck M, Moura C, Winthrop K, Machado M, Neville A, Bernatsky S
Clin Infect Dis
. 2024 Nov;
80(2):314-315.
PMID: 39589137
Antibiotic prophylaxis is often recommended for close contacts of index cases of invasive Streptococcus pyogenes infections. Using MarketScan data (2010-2019), we found no difference in infection rates between those who...
5.
Birck M, Lukusa L, Choquette D, Boire G, Maksymowych W, Singh H, et al.
BMC Rheumatol
. 2024 Sep;
8(1):47.
PMID: 39343928
Background: Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments. Using Canadian administrative health data...
6.
Hitchon C, Bowdish D, Boire G, Fortin P, Flamand L, Chandran V, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340091
SARS-CoV-2 remains the third most common cause of death in North America. We studied the effects of methotrexate and tumor necrosis factor inhibitor (TNFi) on neutralization responses after COVID-19 vaccination...
7.
Tsyruk O, Kaplan G, Fortin P, Hitchon C, Chandran V, Larche M, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340057
We were tasked by Canada's COVID-19 Immunity Task Force to describe severe adverse events (SAEs) associated with emergency department (ED) visits and/or hospitalizations in individuals with immune-mediated inflammatory diseases (IMIDs)....
8.
9.
Mendel A, Behlouli H, Vinet E, Curtis J, Bernatsky S
Rheumatology (Oxford)
. 2024 Jul;
PMID: 39024050
Objective: To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA). Methods: This retrospective cohort study included adults with GPA...
10.
Zhao N, Smargiassi A, Chen H, Widdifield J, Bernatsky S
Arthritis Care Res (Hoboken)
. 2024 Jul;
77(1):15-22.
PMID: 39014888
Objective: Exposure to fine particulate matter (PM) has been linked to many diseases. However, it remains unclear which PM chemical components for these diseases, including rheumatoid arthritis (RA), are more...